- Home
- SD vs LBRX Comparison
SD vs LBRX Comparison
Compare SD & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SD | LBRX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.7M | 602.6M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | SD | LBRX |
|---|---|---|
| Price | $15.34 | $31.56 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $15.00 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 302.7K | 287.8K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 12.43 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.65 | N/A |
| Revenue Next Year | $1.75 | N/A |
| P/E Ratio | $8.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.11 | $13.40 |
| 52 Week High | $18.45 | $33.47 |
Technical Indicators
Market Signals| Indicator | SD | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 63.59 |
| Support Level | $15.04 | $21.90 |
| Resistance Level | $15.56 | N/A |
| Average True Range (ATR) | 0.34 | 1.93 |
| MACD | 0.12 | 0.08 |
| Stochastic Oscillator | 78.14 | 76.76 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.